Offerings, buyouts and cancer trials have these guys moving 🔥

Be the best prepared trader on the Street!                                                                                                                                                                                                                                                                                                                                                                                                                 September 13, 2024 | [Read Online]( In partnership with Good day, 360! Here are our top investing ideas today. And don’t forget to join us in [Market Masters]( - the hottest trading room around 🔥. Be the best prepared trader on the Street! FOCUS LIST🔎 TNON - Up over 400% in the pre-market after announcing pricing of $4.5 Million public offering priced At-The-Market under Nasdaq rules OMIC - Up over 60% in pre after receiving non-binding acquisition proposal from Deerfield IMRX - Up over 35% in pre after announcing positive initial Phase 2a data including complete and partial responses with IMM-1-104 in combination with chemotherapy in first-line Pancreatic Cancer patients *sponsored by Vinovest Whiskey: A Hedge Against Market Volatility Looking to protect your portfolio from the next recession? Consider investing in rare spirits like whiskey. Whiskey investing provides a proven hedge against stock market dips driven by inflation and other factors. With [Vinovest](, you can invest in high-growth segments such as American Single Malt, emerging Scotch, Bourbon, and Irish whiskey. Thanks to established industry relationships, Vinovest overcomes industry barriers that have made historically whiskey investing expensive and opaque. As a result, you can enjoy high-quality inventory that boosts your portfolio value and enhances liquidity. [Schedule a call with a Vinovest advisor to learn more.]( HOTLIST🔥 TNON - Up over 400% in the pre-market after announcing pricing of $4.5 Million public offering priced At-The-Market under Nasdaq rules Tenon Medical Inc. (TNON) is a medical device company that engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. Late yesterday, the [company announced]( the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $3.55 per share, will be exercisable immediately and will expire five years from the issuance date. The closing of the Offering is expected to occur on or about September 16, 2024, subject to the satisfaction of customary closing conditions. TNON had a float of only 460,000 shares according to Finviz based on yesterday’s close. The stock traded up over 400% in the pre-market this morning. The $13.50 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $17.50, $20, $25 and then $29.88. Below $13.50, targets to the downside are $11.50, $9.62, $7.50, $5 and then a gap fill at $4.40. OMIC - Up over 60% in pre after receiving non-binding acquisition proposal from Deerfield Singular Genomics Systems, Inc. (OMIC) is a life science technology company that develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. In the pre-market this morning, the [company announced]( that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company’s outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company. The stock traded up over 60% in the pre-market in reaction to the news. The first target for bulls is $9 and then the pre-market high at $9.53. Beyond that, $10, $11 and $12.37 come into play. Below $9, targets to the downside are $8.50, $7.75, $7, $6 and then a gap fill at $5.65. IMRX - Up over 35% in pre after announcing positive initial Phase 2a data including complete and partial responses with IMM-1-104 in combination with chemotherapy in first-line Pancreatic Cancer patients Immuneering Corporation (IMRX) is a clinical-stage oncology company that engages in the development of medicines for broad populations of cancer patients. In the after-hours yesterday, the [company announced]( positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial. Highlights include: - In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Clear path forward expected for clinical development of IMM-1-104 in combination with gemcitabine/nab-paclitaxel for pancreatic cancer, assuming initial data is representative; FDA previously granted IMM-1-104 Fast Track designation for the treatment of first- and second-line pancreatic ductal adenocarcinoma - - Enrollment progressing in all Phase 2a arms with further data expected by year end - The stock traded up over 35% in the pre-market in reaction to the positive results. The $1.95 area acted as support in the after-hours and then resistance in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.12, $2.20, $2.30 and then the pre-market high at $2.63. Beyond that, $3 and $3.20 come into play. Below $1.95, targets to the downside are $1.80, $1.60, $1.50 and then a gap fill at $1.43. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](